Helsinki, October 21, 2025 – MVision AI, a leading provider of vendor-neutral AI solutions for radiotherapy, proudly announces that its Workspace+ platform has received CE marking as a Class IIa medical device under the EU Medical Device Regulation (MDR 2017/745).
The certification marks a significant regulatory milestone, officially recognising Workspace+ as an AI-powered solution that automates radiotherapy workflows — from imaging to treatment planning. The web-based platform supports clinicians in standardising, reviewing, and adapting the course of treatment while enabling faster and more informed decision-making.
“With CE Class IIa approval, Workspace+ becomes one of the first truly cloud-native, vendor-neutral solutions to unify AI-powered contouring, dose prediction, synthetic CT generation, and contour propagation in a single platform,” said Mahmudul Hasan, Founder and CEO of MVision AI. “This milestone brings us closer to our mission of supporting same-day radiotherapy — helping clinicians make timely decisions and reducing waiting times and worry for patients.”
About Workspace+
Workspace+ serves as the central platform for MVision’s expanding suite of AI solutions — Contour+ for auto-contouring, Dose+ for dose prediction, Image+ for synthetic imaging, and Adapt+ for contour propagation — helping streamline key parts of the radiotherapy planning workflow.
Designed for clinical efficiency and interoperability, Workspace+ integrates seamlessly with hospital PACS, treatment planning systems, and oncology information systems — providing clinicians with:
- Unified access to multiple AI applications and imaging tools
- Cloud-native scalability with robust security and GDPR/HIPAA compliance
- Workflow automation that accelerates planning and standardises quality
With the CE mark in place, Workspace+ is now cleared for clinical use across Europe and other MDR-recognized markets.
The official launch of Workspace+ is coming soon. Stay tuned to MVision AI’s website and social media channels.
About MVision AI
Founded in 2017, MVision AI is a Finland-based health-tech company transforming radiotherapy planning through artificial intelligence. Its solutions are trusted by leading cancer centres in over 24 countries, enabling clinicians to deliver faster, more consistent, and patient-specific treatments.
MVision’s mission is to make same-day radiotherapy a reality — ensuring every patient gets the best possible care, on time.
*Workspace+ availability is subject to regulatory approval for global markets.